Dr. Iliana Samara Hurtado Rendon, MD

Dr. Hurtado Rendon practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Hurtado Rendon's NPI, 1548423676, was assigned on July 9, 2008. Dr. Hurtado Rendon holds West Virginia license 29001.

Dr. Hurtado Rendon's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Hurtado Rendon's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Hurtado Rendon to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hurtado Rendon practices, 2 sites in all. Vendor and product names are available with a free account.

Interventional cardiology is Dr. Hurtado Rendon's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Dmand AI has Dr. Hurtado Rendon's licenses on file in 2 states: West Virginia and Ohio.

CMS data shows 132 Medicare services from Dr. Hurtado Rendon across 4 procedure codes in 2024, for 141 Medicare patients. Medicare paid $4,515 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 141 Medicare patients who saw Dr. Hurtado Rendon in 2024. The largest group is 65 to 74, with 56 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hurtado Rendon's median patient age at 72, with 55% women.

In 2024, Dr. Hurtado Rendon wrote 393 Medicare Part D claims for 127 patients. 86% of them were for generic drugs. CMS names the drug for 283 of them, across 12 drugs with 11 or more claims each, at $32,981 in total drug cost. In 2023, CMS named 439 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Hurtado Rendon for performance year 2024, reported through an alternative payment model (APM). Dr. Hurtado Rendon accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hurtado Rendon as offering telehealth.

Dmand AI links 1 paper to Dr. Hurtado Rendon in 2011. Dr. Hurtado Rendon's most frequent co-authors are Vikas Pathak, MD and Mihai Smina, MD.

CMS Open Payments shows 69 general payments to Dr. Hurtado Rendon from 17 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 55% of the total. Abiomed paid the most, $2,756.